摘要
血脂异常和炎症是促进动脉粥样硬化发生发展且与之密切相关的两个关键因素。近年研究显示,他汀类药物、胆固醇吸收抑制剂依折麦布、前蛋白转化酶枯草溶菌素9/kexin 9 型(proprotein convertase subtilisin/kexin type 9,PCSK9)抑制剂等调脂药物可能具有独立于降胆固醇之外的抗炎和免疫调节作用,其可抑制动脉粥样硬化进展,减少心血管事件。同时,这些调脂药物还可能通过抗炎作用改善类风湿关节炎、脂肪性肝炎、脓毒症等炎症性疾病的预后。
Dyslipidemia and inflammation are closely interconnected key drivers of atherosclerosis. Recent studies have shown that lipid-regulating drugs such as Statin, cholesterol absorption inhibition Ezetimibe, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors may have anti-inflammatory and immunomodulatory effects independent of cholesterol lowering, inhibit the progress of atherosclerosis and reduce cardiovascular events. At the same time, these lipid-regulating drugs may also improve the prognosis of other inflammatory diseases such as rheumatoid arthritis, steatohepatitis and sepsis through anti-inflammatory effects.
作者
苏冠华
程翔
SU Guan-hua;CHENG Xiang(Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Scienceand Technology, Wuhan 430022,China)
出处
《中国医学前沿杂志（电子版）》
2019年第5期1-5,共5页
Chinese Journal of the Frontiers of Medical Science(Electronic Version)
基金
国家自然科学基金资助项目(81700345)
